Biotechnology 
This is an OPML file. It can be used to export all the MedWorm RSS feeds on this topic into your personal RSS reader (usually you have to save this file to your own computer before clicking on an Import OPML command in your own feed reader to upload the file which will then import all the feeds) or it can be used by webmasters to integrate MedWorm feeds with their own website. 
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader, such as GoogleReader, or to display this data on your own website or blog. 
Subscribe to this data using MyMedWorm.
Subscribe to this data using GoogleReader.
Subscribe to this data using Bloglines.
Subscribe to this data using MyYahoo.
Please support the Doctors In Chains campaign for the medics tortured and sentenced for up to 15 years in Bahrain. #FreeDoctors
This page shows you the most recent publications within this specialty of the MedWorm directory.
85180 records returned
Coventry renews contract with CEO Allen Wise
Email this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Coventry Health Care Inc. has extended CEO Allen Wise's contract for two years, securing his services through Dec. 31, 2013, and boosting his compensation to new heights.
Effective Jan. 1, Wise earns $900,000 in base salary annually and will be eligible for up to $1.8 million in bonuses each year, according to a Securities and Exchange Commission filing made public Monday. Furthermore, Wise will receive $7.6 million worth of stock awards in both 2012 and 2013 that would become payable upon the the health insurer's reaching earnings-per-share and revenue targets... (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - February 6, 2012 Category: Biotechnology Authors: Ben Fischer Source Type: research
Five Prime Therapeutics Inc. makes interim CEO officialEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Five Prime Therapeutics Inc. made Lewis Williams, M.D., president and CEO, thus confirming him in a job he’s held temporarily since August.
Williams, who started Five Prime, worked in the past at Chiron Corp. and at the University of California, San Francisco. He was also on the faculty at Harvard Medical School and was a staff cardiologist at Massachusetts General Hospital.
He’s been temporary CEO of Five Prime since Julia Gregory quit as CEO last summer. Gregory herself had replaced CEO Gail Maderis in 2009... (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - February 6, 2012 Category: Biotechnology Authors: Steven E.F. Brown Source Type: research
Lincare income drops despite revenue gainEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Lincare Holdings Inc. reported net income for 2011 of $177.3 million, or $1.93 a share, compared to net income of $181.6 million, or $1.87 a share, in 2010.
Although profit dropped, earnings per share increased in 2011 because Lincare had about 10.2 million fewer shares outstanding as of Dec. 31.
Revenue for 2011 was $1.85 billion, a 10.7 percent increase over revenue of $1.7 billion in 2010, a statement from the company said.
For the fourth quarter of 2011, Lincare reported net income of $44... (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - February 6, 2012 Category: Biotechnology Source Type: research
Cardica loses $3.2 million in Q2, borrows $2 millionEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Cardica Inc., which makes surgical devices, lost $3.2 million in the December quarter, its second, and borrowed $2 million from Century Medical Inc. on Dec. 27.
Redwood City-based Cardica (NASDAQ: CRDC) had an earlier secured debt deal with Japan’s Century Medical, an arrangement with $2 million left on it. Cardica made a distribution deal with Century Medical in September, and had already borrowed $2 million on the $4 million total allowed in the debt agreement.
In the second quarter, Cardica lost $3... (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - February 6, 2012 Category: Biotechnology Authors: Steven E.F. Brown Source Type: research
Parkland: Monitor's report 'humbling'Email this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Parkland Memorial Hospital's board released a statement today calling the results of an outside safety monitor's report "humbling" but refused to release the findings.
"While Parkland can be proud of our many accomplishments, the report makes it clear that we have not consistently delivered on our commitment to safety and accountability," said a statement read by Dr. Lauren McDonald, chairwoman of the Parkland Board of Managers. "We must change. We have begun, and we will continue."
The statement said the board weighed the duty to be open with the public against the duty to protect the rights of patients and Parkland as ...
Source: bizjournals.com Health Care:Biotechnology headlines - February 6, 2012 Category: Biotechnology Authors: Bill Hethcock Source Type: research
Omnicare executive departs with $1M in severanceEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Leo Finn has resigned as Omnicare Inc.’s executive vice president for strategic planning and corporate development, taking with him more than $1 million in severance and other payments.
The resignation, dated Feb. 3, was effective Feb. 1. Omnicare did not provide an explanation for the 22-year veteran’s departure.
The separation agreement provides Finn with aggregate cash severance of $320,000, payable in 12 monthly installments, according to a filing that Covington-based Omnicare made with the U... (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - February 6, 2012 Category: Biotechnology Authors: James Ritchie Source Type: research
Craig Phelps to take over as A.T. Still presidentEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Dr. Craig Phelps, who currently serves as senior vice president for strategic initiatives for A.T. Still University, has been promoted to president of the university.
He will split his time between ATSU’s main campus in Kirksville, Mo., and its Mesa campus. He is replacing Jack Magruder, who announced his retirement several months ago. His new role becomes effective July 1.
Phelps is a 1984 graduate of ATSU’s Kirksville College of Osteopathic Medicine. He became provost of its Arizona campus in 1998 and led the team that developed that campus and its three academic units — the Arizona School of Health Sciences, the...
Source: bizjournals.com Health Care:Biotechnology headlines - February 6, 2012 Category: Biotechnology Authors: Angela Gonzales Source Type: research
GlaxoSmithKline 'finding' halts four trials of Anacor antibioticEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
GlaxoSmithKline plc suspended enrollment in four trials of an Anacor Pharmaceuticals Inc. antibiotic after a “microbiological finding” in some patients in one of the studies.
The stock of Palo Alto-based Anacor (NASDAQ: ANAC) was down 36 cents, or nearly 5 percent, to $7.06 per share by mid-afternoon, after GSK said Monday that it suspended enrollment around GSK-052 in patients with complicated urinary tract infections.
The finding isn’t related to three other studies of the drug — a Phase IIb trial in complicated intra-abdominal infections and two Phase I trials — but GSK said it voluntarily suspended enrollme...
Source: bizjournals.com Health Care:Biotechnology headlines - February 6, 2012 Category: Biotechnology Authors: Ron Leuty Source Type: research
Temple names director for translational medicine centerEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Temple University School of Medicine has recruited Walter Koch to serve as director of the university’s newly established center for translational medicine.
Koch, who will also serve as a professor of pharmacology at the Temple medical school, was previously at Jefferson Medical College in Philadelphia where he was director of translational medicine and vice chairman of research.
Translational medicine is a growing field dedicated to accelerating the process of turning biological discoveries into drugs and medical devices that can be used to treat patients... (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - February 6, 2012 Category: Biotechnology Authors: John George Source Type: research
Smith & Nephew settles Greek bribery case for $22.2MEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Smith & Nephew Inc. is paying $22.2 million to settle U.S. criminal and civil allegations that it bribed doctors employed by the Greek government to win business.
The amount includes a $16.8 million fine that must be paid by Memphis-based Smith & Nephew Orthopaedics, the company’s subsidiary.
The Memphis division merged with another company division in Andover, Mass., last year to create the Advanced Surgical Devices Division.
Under the agreement, Smith & Nephew has to internally monitor corporate activities to prevent bribery and hire a compliance expert for 18 months... (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - February 6, 2012 Category: Biotechnology Authors: Michael Sheffield Source Type: research
Let the country, not the City, drive the UK economy | Colin TudgeEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
In one Oxfordshire village, an idea is gathering traction: that it's time for a new agricultural revolutionOxford city council has decided that we need more houses and jobs – not least in my own village of Wolvercote, to the north-west of the city. Under the coalition's neighbourhood development order (part of the localism bill) we, the yokels, the ordinary Joes, have some say in what should be done.So now we plot and ponder in the village hall – and we are witnessing what I hope will prove to be a seismic shift in public mood, in the economy, and in the balance of power. For more and more people are beginning to feel ...
Source: Guardian Unlimited Science - February 6, 2012 Category: Science Authors: Colin Tudge Tags: Farming Environment Agriculture Economic policy Economic growth (GDP) Economics Business Rural affairs Science Politics UK news guardian.co.uk Comment Comment is free Source Type: news
National Professional Science Master's Association Presents...Email this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
“Preparing Graduates for Challenging and Rewarding Careers in the Biotechnology Industry”(PRWeb February 03, 2012)Read the full story at http://www.prweb.com/releases/2012/2/prweb9159630.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - February 6, 2012 Category: Pharmaceuticals Source Type: news
Cancer Center, in Suit, Claims Ex-Official Took ResearchEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
The president of Memorial Sloan-Kettering Cancer Center, Dr. Craig B. Thompson, is in a billion-dollar dispute with his former workplace over accusations that he walked away with research. (Source: NYT Health)
Source: NYT Health - February 6, 2012 Category: Consumer Health News Authors: By ANDREW POLLACK Tags: Memorial Sloan-Kettering Cancer Center University of Pennsylvania Suits and Litigation Intellectual Property Colleges and Universities Research Biotechnology Celgene Corporation CELG NASDAQ Aetna Inc AET NYSE Nektar Therapeutics NKTR NAS Source Type: news
Piramal doubles stake in Vodafone at cheaper priceEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Piramal-Vodafone deal, which is more profitable for the Piramal group, represents both groups biding time, towards separate objectives. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - February 4, 2012 Category: Pharmaceuticals Source Type: news
MonaVie plans manufacturing facility in South IndiaEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
MonaVie would launch its products in India by May and plans to set up a manufacturing facility in South India, a top official said. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - February 4, 2012 Category: Pharmaceuticals Source Type: news
Piramal Healthcare to buy 5.5 pct of Vodafone India unitEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
The sale would mark the exit of Essar as Vodafone's JV partner in India after the London-listed co last year sealed a long awaited deal to buy out Essar. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - February 4, 2012 Category: Pharmaceuticals Source Type: news
Fortis invests SGD70 million in 2 Singapore healthcare venturesEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Indian healthcare group Fortis is investing SGD 70 million (about Rs 274 crore) in two colorectal centres in Singapore this year, a report said today. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - February 4, 2012 Category: Pharmaceuticals Source Type: news
Response Genetics raises $7.8 million in stock saleEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Response Genetics Inc. said it has raised more than $7.8 million through the private placement of 5.3 million in newly issued stock.
The Los Angeles-based company, which makes molecular diagnostic tests for cancer, said it sold the shares to undisclosed investors for $1.50 a share, a premium of 27 percent above its closing stock price of $1.18 a share on Wednesday.
New investors accounted for the majority of the financing, while existing investors, as well as board members and senior management, made up the remainder, Response Genetics said... (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - February 3, 2012 Category: Biotechnology Source Type: research
Schizophrenia pill Olanzapine, weak rupee drive Dr Reddy’s Lab topline to Rs 2,770 croreEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Dr Reddy’s Laboratories’ revenues in the December quarter jumped to Rs 2,770 crore, buoyed by the launch of a star performing drug and a weak rupee with the highest-ever year-on-year growth of 46%. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - February 3, 2012 Category: Pharmaceuticals Source Type: news
Cempra enjoys modest gain on tradingEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Shares of Chapel Hill drug developer Cempra (Nasdaq: CEMP) opened at $6.20 on its first day of trading as a public company, up 3.3 percent from the IPO price of $6. A total of 8.4 million shares at a price well below the expected $11 to $13. For more, go here.
Cempra is headed by CEO Prabha Fernandes. (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - February 3, 2012 Category: Biotechnology Authors: Dale Gibson Source Type: research
Alabama lawmakers file bills to legalize medical marijuanaEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Two Alabama House members from opposing parties have filed similar bills seeking to legalize the medical use of marijuana.
With the 2012 session to begin Tuesday, Rep. Patricia Todd (D-Birmingham) is again carrying a bill that would allow qualifying patients to possess up to 2.5 ounces of marijuana if prescribed by a physician.
Meanwhile, Rep. K.L. Brown, R-Jacksonville, a funeral home owner who says his sister used marijuana to control pain before her death from breast cancer 25 years ago, has filed a similar bill... (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - February 3, 2012 Category: Biotechnology Authors: Evan Belanger Source Type: research
President, CFO leave HealthSpring following Cigna dealEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Two executives have left HealthSpring following the company's merger with Cigna, which closed earlier this week.
Karey Witty, executive vice president and chief financial officer of HealthSpring, and Michael Mirt, president of the company, are no longer with the company, as of Jan. 31, the day Cigna’s $3.8 billion acquisition of Franklin-based HealthSpring was finalized.
Mirt's duties will split between two HealthSpring executive vice presidents, Shawn Morris and Scott Huebner. Morris will be president of operations, and Huebner president of clinical operations... (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - February 3, 2012 Category: Biotechnology Authors: Chris Silva Source Type: research
Stanley Black & Decker, Adventist cutting 242 jobs in Baltimore areaEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Stanley Black & Decker is closing a West Baltimore facility and cutting 142 jobs, according to a notice with the state’s labor department. Meanwhile, Adventist Behavioral Health is closing a Crownsville facility and laying off 100 people, a separate filing with the state said.
Stanley Black & Decker plans to close its Baltimore Protection Net Center on Sisson Street, the filing said. The layoffs will take place in waves, starting April 1-14, and ending with a Oct. 23-Nov. 6 wave.
Adventist is closing a treatment facility and school in Crownsville on March 31... (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - February 3, 2012 Category: Biotechnology Authors: Ryan Sharrow Source Type: research
Austin-based Hanger revamps its brandEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Hanger Orthopedic Group Inc., a manufacturer and provider of prosthetics, orthotics and related services, has unveiled a new name, logo and strategy.
The Austin-based company plans to shorten its name to Hanger (NYSE: HGR), and change its clinic business, now called Hanger Prosthetics & Orthotics, to Hanger Clinic. The company’s shareholders are expected to approve the name changes at the annual shareholder meeting in May.
The company has developed a new logo to compliment the name changes called Empower Mark, that “symbolizes a beacon of hope for Hanger’s clients,” company officials said... (Source: bizjournals....
Source: bizjournals.com Health Care:Biotechnology headlines - February 3, 2012 Category: Biotechnology Authors: Sandra Zaragoza Source Type: research
Biocon keeps hopes of overseas sales under checkEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
"Any partner who looks at this asset will back-load the payment because while the market is huge, we still don't know if the drug works the way we want," company's founder chairman told. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - February 3, 2012 Category: Pharmaceuticals Source Type: news
Talon leukemia drug gets date with FDA advisory panelEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Talon Therapeutics Inc. must hurdle a Food and Drug Administration advisory panel March 21 before its experimental leukemia drug can be approved.
San Mateo-based Talon (OTCBB: TLON) said Friday that its drug Marqibo will be assessed by the FDA’s oncology drugs advisory committee for treating adult Philadelphia chromosome-negative acute lymphoblastic leukemia, a rare blood cancer.
“We believe Marqibo has the potential to help a near end-stage leukemia population of patients without good treatment options,” Talon President and CEO Dr... (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - February 3, 2012 Category: Biotechnology Authors: Ron Leuty Source Type: research
Susan G. Komen reverses Planned Parenthood funding moveEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
The Susan G. Komen for the Cure Foundation on Friday said it has reversed its decision about funding grants for Planned Parenthood.
The organization, which has Cincinnati affiliate, said earlier this week that it would not fund grant applications to groups under federal investigation, which includes Planned Parenthood.
Culture Map reports that after the initial Komen announcement, Planned Parenthood received more than $400,000 in donations in 24 hours.
A Friday statement from Nancy Brinker, the founder of the foundation, apologized for upsetting its supporters and partners with the funding removal, and said the foundati...
Source: bizjournals.com Health Care:Biotechnology headlines - February 3, 2012 Category: Biotechnology Source Type: research
State health funds to boost Dayton groupsEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
The Ohio Department of Health has awarded two grants worth a combined $65,000 to the Alcohol, Drug Addiction & Mental Health Services Board for Montgomery County.
One grant, worth $40,000, will go toward programs for mental health consultation, assessments and treatment of children from birth to 5 years old who are at risk of removal from their custodial home, are victims of abuse or neglect or are entering foster care. Those dollars also can be used to help educate biological and foster parents of children in the welfare system... (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - February 3, 2012 Category: Biotechnology Authors: Laura Englehart Source Type: research
Susan G. Komen reverses Planned Parenthood funding moveEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
The Susan G. Komen for the Cure Foundation on Friday said it has reversed its decision about funding grants for Planned Parenthood.
The organization, which has an Albany, New York, affiliate, said earlier this week that it would not fund grant applications to groups under federal investigation, which includes Planned Parenthood.
Culture Map reports that after the initial Komen announcement, Planned Parenthood received more than $400,000 in donations in 24 hours.
A Friday statement from Nancy Brinker, the founder of the foundation, apologized for upsetting its supporters and partners with the funding removal, and said th...
Source: bizjournals.com Health Care:Biotechnology headlines - February 3, 2012 Category: Biotechnology Source Type: research
Pharmaceutical Legislation Changes In Europe - EMA and Member States PrepareEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Preparations are underway at the European Medicines Agency together with European Member States and the European Commission, for the introduction of the new pharmacovigilance legislation in July this year. The new legislation will represent the biggest change to the legal framework since The Agency was founded in 1995. The Agency is finalizing their preparations for the inaugural meeting of the new Pharmacovigilance Risk Assessment Committee (PRAC), which is scheduled for 19 July 2012... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - February 3, 2012 Category: Consumer Health News Tags: Pharma Industry / Biotech Industry Source Type: news
Big Biotech and Big Pharma: no place to hide?Email this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
The importance of continued pressure amid European corporate pullouts (Source: Alliance for Natural Health)
Source: Alliance for Natural Health - February 3, 2012 Category: Complementary Medicine Authors: Adam Tags: biotech brazil brics china drugs EU europe GM GMO gmos india international pharma pharmaceuticals russia south africa Source Type: news
Improving test properties for neonatal cystic fibrosis screening in the Netherlands before the nationwide start by May 1st 2011Email this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Abstract When new technical possibilities arise in health care, often attunement is needed between different actors from the perspectives
of research, health care providers, patients, ethics and policy. For cystic fibrosis (CF) such a process of attunement in
the Netherlands started in a committee of the Health Council on neonatal screening in 2005. In the balancing of pros and cons
according to Wilson and Jungner criteria, the advantages for the CF patient were considered clear, even though CF remains
a severe health problem with treatment. Nevertheless, screening was not started then, mainly since the spec...
Source: Journal of Inherited Metabolic Disease - February 3, 2012 Category: Internal Medicine Tags: Journal of Inherited Metabolic Disease Source Type: research
Eclipse Therapeutics Appoints Hans Clevers, M.D., Ph.D., and Thomas...Email this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Eclipse Therapeutics, Inc., a biotechnology company dedicated to the discovery and development of novel therapeutics that target cancer stem cells, announced today the appointments of Hans Clevers,...(PRWeb February 01, 2012)Read the full story at http://www.prweb.com/releases/2012/2/prweb9155733.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - February 3, 2012 Category: Pharmaceuticals Source Type: news
Norwich Expands Capabilities for Phase I-III Clinical TrialsEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Norwich Clinical Services (NCS), a global provider of clinical research services for the pharmaceutical and biotech industries, today announced an expansion at two research facilities in order to meet...(PRWeb February 02, 2012)Read the full story at http://www.prweb.com/releases/NorwichExpands/ClinicalResearch/prweb9160796.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - February 3, 2012 Category: Pharmaceuticals Source Type: news
Deciphering the role of Paenibacillus strain Q8 in the organic matter recycling in the acid mine drainage of CarnoulesEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Conclusions:
AMDs have been studied for years especially with regard to interactions between bacteria and the inorganic compartment hosting them. To date, no study reported the role of microorganisms in the recycling of the organic matter. The present work suggests that the strain Q8 might play an important role in the community by recycling the scarce organic matter (cellulose, hemicellulose, starch...), especially when the conditions change. Furthermore, function-based screening of a Q8 DNA library allowed to assign an amylolytic function to a gene previously unknown. AMDs could be considered as a reservoir of genes with...
Source: Microbial Cell Factories - February 3, 2012 Category: Microbiology Authors: Francois DelavatVincent PhalipAnne ForsterMarie-Claire LettDidier Lievremont Source Type: research
Drug firm Indoco Remedies ties up with DSM pharmaEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Drug firm Indoco Remedies has entered into a marketing pact with DSM Pharmaceutical Products NV which will sell its products in Austria and other int'l mkts. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - February 2, 2012 Category: Pharmaceuticals Source Type: news
State Bank of Mysore files criminal complaint against Sterling BiotechEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
State Bank of Mysore has filed a criminal complaint against Sterling Biotech, and its six directors, for allegedly defaulting on repayments. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - February 2, 2012 Category: Pharmaceuticals Source Type: news
Fortis Healthcare mulls hiving off non-core businessEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Fortis Healthcare Ltd, the country's largest hospital company, plans to hive off its non-core business and related assets into a separate company. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - February 2, 2012 Category: Pharmaceuticals Source Type: news
Auxogyn raises $20M in Series A fundsEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Auxogyn Inc. said Thursday it has closed of the final tranche of its Series A funding.
The private Menlo Park-based company is focused on advancing women's reproductive health and has raised $20 million to date. It specializes in a non-invasive early embryo viability assessment system called Eeva.
According to a prepared statement, the initial tranche was placed in May 2010, and investors in the round include Menlo Park-based Kleiner Perkins Caufield & Byers, San Francisco-based TPG Biotech and Merck Serono Ventures, the strategic venture capital fund of Merck Serono, the division for biopharmaceuticals of German chemica...
Source: bizjournals.com Health Care:Pharmaceuticals headlines - February 2, 2012 Category: Pharmaceuticals Source Type: research
'Yellow biotechnology': Using plants to silence insect genes in a high-throughput mannerEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
'Yellow biotechnology' refers to biotechnology with insects -- analogous to the green (plants) and red (animals) biotechnology. Active ingredients or genes in insects are characterized and used for research or application in agriculture and medicine. Scientists in Germany are now using a procedure which brings forward ecological research on insects: They study gene functions in moth larvae by manipulating genes using the RNA interference technology (RNAi). RNAi is induced by feeding larvae with plants that have been treated with viral vectors. This method -- called "plant virus based dsRNA producing system" (VDPS) -- incre...
Source: ScienceDaily Headlines - February 2, 2012 Category: Science Source Type: news
Should we really fear 'new flesh-eating bacteria'?Email this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Conclusion
This interesting study helps explain why healthcare-acquired MRSA infections are rarely found in healthy individuals. It found that expression of a gene that produces one of the proteins responsible for MRSA’s antibiotic resistance caused it to be less toxic. It also showed that typical community-acquired MRSA strains express less of this antibiotic-resistance protein, but are more toxic.
However, this intriguing lab study did not investigate the transmission, effects or number of cases of community-acquired MRSA in the UK, discussion of which formed the majority of the news reports. On this basis, the researc...
Source: NHS News Feed - February 2, 2012 Category: Consumer Health News Tags: Medical practice Source Type: news
Norwich Expands Capabilities For Phase I-III Clinical TrialsEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Norwich Clinical Services (NCS), a global provider of clinical research services for the pharmaceutical and biotech industries, recently announced a significant expansion to its clinical research capabilities in order to meet growing market demand. (Source: Pharmaceutical Online News)
Source: Pharmaceutical Online News - February 2, 2012 Category: Pharmaceuticals Source Type: news
Help stop former Monsanto VP from attaining top position at the FDA - sign the petitionEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
The one man who may be responsible for more food related illnesses and deaths than anyone in history, Michael R. Taylor, has just been promoted from US Food Safety Czar to Senior Advisor to the Commissioner of the FDA, a position which would enable the giant biotech... (Source: NaturalNews.com)
Source: NaturalNews.com - February 2, 2012 Category: Consumer Health Advice Source Type: news
Expressed Sequences and Polymorphisms in Rohu Carp (Labeo rohita, Hamilton) Revealed by mRNA-seq.Email this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Abstract
Expressed genes and polymorphisms were identified in lines of rohu Labeo rohita selected for resistance or susceptibility to Aeromonas hydrophila, an important bacterial pathogen causing aeromoniasis. All animals were grown in a common environment and RNA from ten individuals from each line pooled for Illumina mRNA-seq. De novo transcriptome assembly produced 137,629 contigs with 40× average coverage. Forty-four percent of the assembled sequences were annotated with gene names and ontology terms. Of these, 3,419 were assigned biological process terms related to "stress response" and 1,939 "immune system"....
Source: Marine Biotechnology - February 2, 2012 Category: Biotechnology Authors: Robinson N, Sahoo PK, Baranski M, Mahapatra KD, Saha JN, Das S, Mishra Y, Das P, Barman HK, Eknath AE Tags: Mar Biotechnol (NY) Source Type: research
Function and biotechnology of extremophilic enzymes in low water activityEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Enzymes from extremophilic microorganisms usually catalyze chemical reactions in non-standard conditions. Such conditions promote aggregation, precipitation, and denaturation, reducing the activity of most non-extremophilic enzymes, frequently due to the absence of sufficient hydration. Some extremophilic enzymes maintain a tight hydration shell and remain active in solution even when liquid water is limiting, e.g. in the presence of high ionic concentrations, or at cold temperature when water is close to the freezing point. Extremophilic enzymes are able to compete for hydration via alterations especially to their surface...
Source: Saline Systems - February 2, 2012 Category: Molecular Biology Authors: Ram KaranMelinda CapesShiladitya DasSarma Source Type: research
The diversity of cyanobacterial metabolism: genome analysis of multiple phototrophic microorganismsEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Conclusions:
Our results have direct implications for resource allocation and further sequencing projects. It can be extrapolated that the number of newly identified genes still significantly increases with increasing number of new sequenced genomes. Furthermore, genome analysis of multiple phototrophic strains allows us to obtain a detailed picture of metabolic diversity that can serve as a starting point for biotechnological applications and automated metabolic reconstructions. (Source: BMC Genomics - Latest articles)
Source: BMC Genomics - Latest articles - February 2, 2012 Category: Genetics & Stem Cells Authors: Christian BeckHenning KnoopIlka AxmannRalf Steuer Source Type: research
Applications of peptide nucleic acids (PNAs) and locked nucleic acids (LNAs) in biosensor development.Email this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Abstract
Nucleic acid biosensors have a growing number of applications in genetics and biomedicine. This contribution is a critical review of the current state of the art concerning the use of nucleic acid analogues, in particular peptide nucleic acids (PNA) and locked nucleic acids (LNA), for the development of high-performance affinity biosensors. Both PNA and LNA have outstanding affinity for natural nucleic acids, and the destabilizing effect of base mismatches in PNA- or LNA-containing heterodimers is much higher than in double-stranded DNA or RNA. Therefore, PNA- and LNA-based biosensors have unprecedented se...
Source: Analytical and Bioanalytical Chemistry - February 2, 2012 Category: Chemistry Authors: Briones C, Moreno M Tags: Anal Bioanal Chem Source Type: research
Effect of Costus igneus stem extract on calcium oxalate urolithiasis in albino ratsEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Abstract The effects of aqueous and ethanolic extracts of Costus igneus (stem) and isolated compounds lupeol and stigmasterol on calcium oxalate urolithiasis have been studied in male albino Wistar
rats. Ethylene glycol feeding resulted in hyperoxaluria as well as increased renal excretion of calcium and oxalate. The increased
deposition of stone-forming constituents in the urine, serum, and kidney homogenate of urolithic rats was significantly (p < 0.05) lowered by treatment using aqueous and ethanolic extracts of C. igneus (stem), and isolated compounds lupeol and stigmasterol. The calcium oxala...
Source: Urological Research - February 1, 2012 Category: Urology & Nephrology Tags: Urological Research Source Type: research
Antibiotic susceptibility profiles and first report of TEM extended-spectrum β-lactamase in Pseudomonas fluorescens from coastal waters of the Kaštela Bay, CroatiaEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Abstract The aim of this study was to investigate the antibiotic susceptibility profiles and the presence of extended-spectrum-β-lactamases
(ESBLs) in Pseudomonas fluorescens isolates from coastal waters of the Kaštela Bay, Croatia. Twenty-two water samples were collected during 2009. Isolates were
tested for susceptibilities to 13 antibiotics by Etest. ESBL production was confirmed by double-disk synergy test carried
out on Mueller–Hinton agar plates containing efflux pump inhibitor Phe-Arg-β-naphthylamide dihydrochloride. PCR and DNA sequencing
analysis were used to identify ESBL-encoding genes. The t...
Source: World Journal of Microbiology and Biotechnology - February 1, 2012 Category: Microbiology Tags: World Journal of Microbiology and Biotechnology Source Type: research
NextPharma Technologies Hosts Inauguration Ceremony To Mark Official Opening Of Its 'State Of The Art' Cold Chain And Logistics Warehouse In Werne, GermanyEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
NextPharma, the leading European provider of product development, contract manufacturing and cold chain and logistics outsourcing services to the pharmaceutical
and biotechnology industries, is pleased to announce the official opening of its "state of the art" Cold Chain and Logistics (CLS) warehouse in Werne, Germany at an inauguration ceremony attended by local dignitaries and many of NextPharma's customers. (Source: Pharmaceutical Online News)
Source: Pharmaceutical Online News - February 1, 2012 Category: Pharmaceuticals Source Type: news
